Evasion before invasion: Pre-cancer immunosurveillance.

Carcinogenesis Humans Immunologic Factors Immunotherapy Lung Neoplasms Monitoring, Immunologic Tumor Microenvironment
Preinvasive cancer prevention carcinogenesis immune contexture immune response immunoprevention immunotherapy lung squamous cell carcinoma microenvironment prophylactic

Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
25 04 2021
Historique:
entrez: 17 5 2021
pubmed: 18 5 2021
medline: 3 8 2021
Statut: epublish

Résumé

Early intervention and risk stratification solutions for lung cancer are limited by our understanding of how carcinogenesis transforms the pre-invasive epithelium and its microenvironment before the carcinoma stage. We describe the sequence of molecular and cellular changes leading to cancer formation and the co-evolution of the earliest immune response. We revealed that immune sensing, infiltration and activation of immune cells, immune escape, and microenvironment reorganization occur early in pre-cancer. These findings urge the need for broadening the scope of the established immunotherapy approaches toward prophylactic cancer treatment and preventive intervention. Leveraging the immune contexture and the mechanisms of immune modulation for individuals at risk of developing cancer and further to the general population will allow for early detection, chemoprevention, and risk stratification in the near future.

Identifiants

DOI: 10.1080/2162402X.2021.1912250 PMID: 33996263 PMC: PMC8078715
pubmed: 33996263
doi: 10.1080/2162402X.2021.1912250
pii: 1912250
pmc: PMC8078715
doi:

Substances chimiques

Immunologic Factors 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1912250

Informations de copyright

© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

Références

Nature. 2019 Jul;571(7766):570-575
pubmed: 31243362
Clin Cancer Res. 2017 Sep 1;23(17):5091-5100
pubmed: 28533227
Cancer Res. 2018 Sep 1;78(17):4971-4983
pubmed: 29997230
N Engl J Med. 2020 Feb 6;382(6):503-513
pubmed: 31995683
Oncoimmunology. 2015 Sep 2;5(3):e1088631
pubmed: 27141345
Cell. 2018 Oct 18;175(3):751-765.e16
pubmed: 30318143
Immunity. 2020 Jan 14;52(1):55-81
pubmed: 31940273
Oncoimmunology. 2015 Jan 9;4(4):e974411
pubmed: 26137405
Oncoimmunology. 2014 Jan 1;3(1):e28185
pubmed: 24800178
Lancet Digit Health. 2019 Nov;1(7):e353-e362
pubmed: 32864596
Cancer Cell. 2018 Dec 10;34(6):1012-1026.e3
pubmed: 30537506
Oncoimmunology. 2012 Jul 1;1(4):493-506
pubmed: 22754768
Oncoimmunology. 2015 Dec 8;5(2):e1117740
pubmed: 27057469
Oncoimmunology. 2014 Jan 1;3(1):e27456
pubmed: 24800163
Eur Respir J. 2009 Feb;33(2):352-9
pubmed: 19010987
Nat Med. 2019 Mar;25(3):517-525
pubmed: 30664780
Cancer Discov. 2020 Oct;10(10):1489-1499
pubmed: 32690541
Cell. 2020 Apr 16;181(2):236-249
pubmed: 32302568
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Nat Commun. 2019 Apr 23;10(1):1856
pubmed: 31015447
Oncoimmunology. 2013 Jan 1;2(1):e22789
pubmed: 23482847

Auteurs

Mihaela Angelova (M)

INSERM, Laboratory of Integrative Cancer Immunology, Paris, France.
Equipe Labellisée Ligue Contre Le Cancer, Paris, France.
Centre De Recherche Des Cordeliers, Sorbonne Université, Université De Paris, Paris, France.
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK.

Céline Mascaux (C)

Service De Pneumologie, Hôpitaux Universitaires De Strasbourg, Strasbourg, France.
Université De Strasbourg, Inserm UMR_S 1113, IRFAC, Laboratory Streinth (Stress REsponse and INnovative THerapy against Cancer), ITI InnoVec, Strasbourg, France.

Jérôme Galon (J)

INSERM, Laboratory of Integrative Cancer Immunology, Paris, France.
Equipe Labellisée Ligue Contre Le Cancer, Paris, France.
Centre De Recherche Des Cordeliers, Sorbonne Université, Université De Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Carcinogenèse › Evasion before invasion: Pre-cancer immunosurveillance.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Evasion before invasion: Pre-cancer immunosurveillance.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Facteurs immunologiques › Evasion before invasion: Pre-cancer immunosurveillance.
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Evasion before invasion: Pre-cancer immunosurveillance.
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Evasion before invasion: Pre-cancer immunosurveillance.
questionsmedicales.fr › Techniques d'investigation › Techniques immunologiques › Tests immunologiques › Monitorage immunologique › Evasion before invasion: Pre-cancer immunosurveillance.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Microenvironnement cellulaire › Microenvironnement tumoral › Evasion before invasion: Pre-cancer immunosurveillance.